Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Blood Adv
; 8(6): 1439-1443, 2024 Mar 26.
Article
in En
| MEDLINE
| ID: mdl-38231032
Full text:
1
Database:
MEDLINE
Main subject:
Sulfonamides
/
Leukemia, Lymphocytic, Chronic, B-Cell
Limits:
Humans
Language:
En
Journal:
Blood Adv
Year:
2024
Type:
Article
Affiliation country:
Australia